Research graph
References from Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(20)30045-3 · 2020 · External reference
Chronic Kidney Disease Diagnosis and Management: A Review
10.1001/jama.2019.14745 · 2019 · External reference
Unresolved reference
External reference
Chronic kidney disease
10.1016/s0140-6736(21)00519-5 · 2021 · External reference
The global burden of chronic kidney disease
10.1016/s0140-6736(19)32977-0 · 2020 · External reference
Routine Screening for CKD Should Be Done in Asymptomatic Adults … Selectively
10.2215/cjn.02250314 · 2014 · External reference
Unresolved reference
External reference
Secular Changes in Mortality and Hospitalization over Time in People with Kidney Failure or Severe CKD as Compared with Other Noncommunicable Diseases
10.1681/asn.2020040456 · 2020 · External reference
Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement
10.7326/0003-4819-157-8-201210160-00533 · 2012 · External reference
Unresolved reference
External reference
Screening for Chronic Kidney Disease
10.1001/jama.2015.9425 · 2015 · External reference
Renal Function Trajectory Is More Important than Chronic Kidney Disease Stage for Managing Patients with Chronic Kidney Disease
2012 · External reference
10.1093/ckj/sfv111
10.1093/ckj/sfv111 · External reference
Risk Models to Predict Chronic Kidney Disease and Its Progression: A Systematic Review
10.1371/journal.pmed.1001344 · 2012 · External reference
Risk prediction for chronic kidney disease progression using heterogeneous electronic health record data and time series analysis
10.1093/jamia/ocv024 · 2015 · External reference
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials
10.1053/j.ajkd.2017.10.023 · 2018 · External reference
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
10.1681/asn.2019010007 · 2019 · External reference
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
10.1681/asn.2019010008 · 2019 · External reference
Using CUSUM in real time to signal clinically relevant decreases in estimated glomerular filtration rate
10.1186/s12882-022-02910-8 · 2022 · External reference
Screening for Proteinuria in US Adults: A Cost-effectiveness Analysis
10.1001/jama.290.23.3101 · 2003 · External reference
A Health Policy Model of CKD: 1. Model Construction, Assumptions, and Validation of Health Consequences
10.1053/j.ajkd.2009.11.016 · 2010 · External reference
A Health Policy Model of CKD: 2. The Cost-Effectiveness of Microalbuminuria Screening
10.1053/j.ajkd.2009.11.017 · 2010 · External reference
The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
10.1186/s12882-017-0497-6 · 2017 · External reference
The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease
10.1371/journal.pone.0157323 · 2016 · External reference
Chronic Kidney Disease and Its Complications
10.1016/j.pop.2008.01.008 · 2008 · External reference
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(18)32335-3 · 2018 · External reference
Metabolic Acidosis in CKD: Core Curriculum 2019
10.1053/j.ajkd.2019.01.036 · 2019 · External reference
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
10.1016/j.kint.2017.04.006 · 2017 · External reference
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
10.1001/archinternmed.2009.132 · 2009 · External reference
Healthy Behaviors, Risk Factor Control and Awareness of Chronic Kidney Disease
2013 · External reference
Unresolved reference
External reference
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
10.1016/s2213-8587(19)30256-6 · 2019 · External reference
Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis
10.7326/m22-3228 · 2023 · External reference
Unresolved reference
External reference
Identification and referral of patients with progressive CKD: a national study
10.1053/j.ajkd.2006.04.073 · 2006 · External reference
Predicting Costs Of Care In Chronic Kidney Disease: The Role Of Comorbid Conditions
2006 · External reference
Cost-Effectiveness of Screening for Microalbuminuria among African Americans
10.1681/asn.2012040347 · 2012 · External reference
Unresolved reference
External reference
Measuring the Benefits of Healthcare: DALYs and QALYs–Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions
10.15171/ijhpm.2017.47 · 2017 · External reference
Unresolved reference
External reference
On discount rates for economic evaluations in global health
2020 · External reference
Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
10.1038/s41440-020-00590-1 · 2021 · External reference
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
10.1056/nejmoa1811744 · 2019 · External reference
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
10.1056/nejmoa1515920 · 2016 · External reference
The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
External reference
Dapagliflozin in Patients with Chronic Kidney Disease
10.1056/nejmoa2024816 · 2020 · External reference
Unresolved reference
External reference
Are pharmaceuticals cost-effective? A review of the evidence
10.1377/hlthaff.19.2.92 · 2000 · External reference
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
10.1586/14737167.8.2.165 · 2008 · External reference
Awareness of Chronic Kidney Disease Among Patients and Providers
10.1053/j.ackd.2010.03.002 · 2010 · External reference
Unresolved reference
2019 · External reference
CKD Awareness Among US Adults by Future Risk of Kidney Failure
10.1053/j.ajkd.2020.01.007 · 2020 · External reference
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
10.2337/dc19-s011 · 2019 · External reference
Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines
10.1186/s12882-018-1048-5 · 2018 · External reference
Screening for Chronic Kidney Disease: Recommendation Statement
2014 · External reference
